The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated analysis: Effect of biweekly dosing schedule of trifluridine-tipiracil (TAS-102) on rates of myelosuppression and maintenance of therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC).
 
Christopher G Cann
Consulting or Advisory Role - Curio Science; Targeted Oncology
 
Michael Brian LaPelusa
No Relationships to Disclose
 
Sarah Cimino
No Relationships to Disclose
 
Brian Grieb
No Relationships to Disclose
 
Kristen Keon Ciombor
Consulting or Advisory Role - Lilly; Merck; Personalis; Pfizer; Replimune; Seagen
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Incyte (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Nucana (Inst); Onyx (Inst); Pfizer (Inst); Pfizer/Calithera (Inst); Sanofi (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Array BioPharma
 
Rajiv Agarwal
Honoraria - ASCO; NCCN
 
Satya Das
Honoraria - Ipsen; Novartis; Tersera
 
Laura Williams Goff
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Exelixis; Genentech; Merck; QED Therapeutics
Research Funding - Agios; ASLAN Pharmaceuticals; Basilea; BeiGene; Bristol-Myers Squibb; Merck (Inst)
 
Dana Backlund Cardin
Honoraria - OncLive/MJH Life Sciences
Consulting or Advisory Role - Clarivate
Research Funding - Array BioPharma (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Elicio Therapeutics (Inst); Incyte (Inst); Lilly (Inst); Novartis (Inst); Rafael Pharmaceuticals (Inst); XBiotech (Inst)
 
Shemeka Davis
No Relationships to Disclose
 
Jordan Berlin
Consulting or Advisory Role - Bayer Health; BioSapien; insmed; ipsen; Merck KGaA; Mirati Therapeutics; Oxford BioTherapeutics; qed therapeutics
Research Funding - 23andMe (Inst); Abbvie (Inst); Astellas Pharma (Inst); Atreca (Inst); Bayer (Inst); boston biomedical (Inst); Bristol-Myers Squibb/Celgene (Inst); Day One Biopharmaceuticals (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); I-MAB (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); pfizer (Inst); PsiOxus Therapeutics (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Totus Medicines (Inst); Tyra Biosciences (Inst)
Other Relationship - AstraZeneca; Karyopharm Therapeutics; novocure; Pancreatic Cancer Action Network
 
Cathy Eng
Consulting or Advisory Role - Bayer Health; GlaxoSmithKline; HalioDx; Janssen Oncology; natera
Research Funding - Elevar Therapeutics (Inst); Hutchison China Meditech (Inst)
(OPTIONAL) Uncompensated Relationships - Merck (Inst); Pfizer (Inst)